[
    [
        {
            "time": "2023-10-18",
            "original_text": "Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Migraine",
                    "Injectable",
                    "Biohaven",
                    "Nurtec",
                    "Head-To-Head",
                    "Study"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality速 with Every-Other-Day Nurtec速 ODT for the Preventive Treatment of Migraine",
            "features": {
                "keywords": [
                    "Lilly",
                    "Head-to-Head",
                    "Study",
                    "Emgality",
                    "Nurtec",
                    "Preventive",
                    "Treatment",
                    "Migraine"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality速 with Every-Other-Day Nurtec速 ODT for the Preventive Treatment of Migraine",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]